Latest Asx News

Mineral Resources Limited reported a challenging FY25 half-year with a 9% revenue decline and a 55% drop in underlying EBITDA, yet its Mining Services segment and Onslow Iron project show promising growth trajectories.

Mineral Resources Limited reported a challenging first half of 2025 with significant profit declines amid weaker commodity prices, yet delivered record earnings in Mining Services and advanced its transformative Onslow Iron project.

Mineral Resources Limited posted a substantial $809 million loss for the half-year ending December 2024, driven by lower revenues and significant impairment charges, notably at its Bald Hill lithium project. The company also announced no interim dividend as it focuses on liquidity and operational transitions.

Adriatic Metals has completed a two-tranche institutional placement raising A$80 million to fast-track its Vares Processing Plant expansion and support production growth at Rupice Mine.

Mystate Limited has announced a fully franked ordinary dividend of AUD 0.105 per share for the six months ending December 31, 2024, payable on March 21, 2025. The company’s Dividend Reinvestment Plan remains active, offering shareholders a discounted reinvestment option.

AUCyber Limited has announced a significant reshuffle of its leadership team, appointing Chris Wright as CEO and welcoming three new non-executive directors, signaling a strategic pivot for the cyber security firm.

Bendigo and Adelaide Bank clarifies a modest 5.8% variance in half-year cash earnings against market forecasts, confirming no material surprise and compliance with ASX disclosure rules.

Brisbane Broncos Limited has announced a fully franked ordinary dividend of AUD 0.02 per share for the 2024 financial year, signaling steady returns for shareholders.

FFI Holdings Limited has announced a fully franked ordinary dividend of AUD 0.10 per share for the half-year ending December 2024, payable in April 2025. The company also offers shareholders a Dividend Reinvestment Plan with a 5% discount.

Atturra Limited reports a robust first half of FY25 with revenue growth nearing 28%, driven by recent acquisitions and expanding service offerings, while updating full-year guidance amid cautious government sector risks.

Nyrada Inc. posted a significant $2.46 million loss for H1 FY25, driven by increased R&D spend, while advancing its lead drug NYR-BI03 into first-in-human trials following regulatory approval.

Zelira Therapeutics has received a $1.15 million cash refund from the Australian Government’s R&D Tax Incentive Scheme, bolstering its working capital to advance clinical development and business operations.